OTTAWA, March 25, 2012 /PRNewswire via COMTEX/ --Doctors can now tailor interventional oncology treatment to better meet
Nordion Inc. (TSX: NDN) (NYSE: NDZ),a
leading provider of products and services for the prevention, diagnosis
and treatment of disease, today launched a new custom dose feature in
Europe and Canada for TheraSphere®, Nordion's Y-90 microsphere
treatment for liver cancer. Nordion has also filed a request with the
Food and Drug Administration for approval of the custom dose feature in
the United States.
In addition to standard dose vial configurations, Nordion now offers an
expanded range of TheraSphere treatment options with custom doses
available in wider variety of increments. The custom doses are designed
to provide greater treatment flexibility for physicians, save
administration time and reduce product waste, while limiting
unnecessary radiation exposure to patients and healthcare
Nordion has also enhanced its Treatment Window Illustrator tool to
demonstrate how custom doses can be selected and compared to standard
dose vial configurations.
Nordion is attending the Society of Interventional Radiology (SIR)
Annual Scientific Meeting 2012, March 24-29, in San Francisco. Nordion
representatives will be at Booth #1234 to talk about TheraSphere to physicians attending the conference.
Nordion will host two "Eat and Be Educated" learning sessions at its
Sunday, March 25, 12:15pm
How TheraSphere Y-90 Glass Microspheres Fits in Our Treatment Algorithm
Matthew Johnson, MD
Professor of Radiology and Surgery
Indiana University School of Medicine
Tuesday March 27, 12:15pm
TheraSphere Multi-Vessel Delivery
Siddharth Padia, MD
Assistant Professor, Interventional Radiologist
University of Washington - Harbourview Medical Center
Each session will be followed by a Nordion presentation on how to start
a TheraSphere program.
TheraSphere is a liver cancer therapy that consists of millions of small
glass beads (20 to 30 micrometers in diameter) containing radioactive
yttrium-90 (Y-90). The product is injected by physicians into the
artery of the patient's liver through a catheter, which allows the
treatment to be delivered directly to the tumour via blood flow.
In the US, TheraSphere is used to treat patients with unresectable
hepatocellular carcinoma (HCC), the most common form of primary liver
cancer, and can be used as a bridge to surgery or transplantation in
these patients. It is also indicated for the treatment of HCC patients
with portal vein thrombosis (PVT).TheraSphere is approved by the U.S
Food and Drug Administration (FDA) under a Humanitarian Device
Exemption (HDE). HDE approvals are based on demonstrated safety and
probable clinical benefit. However, effectiveness of the indication for
use has not been established.
TheraSphere® is used in the European Union and in Canada for the
treatment of hepatic neoplasia in patients who have appropriately
positioned arterial catheters.
Common side effects include mild to moderate fatigue, pain and nausea
for about a week. Physicians describe these symptoms as similar to
those of the flu. Some patients experience some loss of appetite and
temporary changes in several blood tests. For details on rare or more
severe side effects, please refer to the TheraSphere package
insert/instructions for use at www.nordion.com/therasphere.
About Nordion Inc.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company
that provides market-leading products used for the prevention,
diagnosis and treatment of disease. We are a leading provider of
medical isotopes, targeted therapies and sterilization technologies
that benefit the lives of millions of people in more than 60 countries
around the world. Our products are used daily by pharmaceutical and
biotechnology companies, medical-device manufacturers, hospitals,
clinics and research laboratories. Nordion has more than 500 highly
skilled employees in three locations. Find out more at www.nordion.com and follow us at http://twitter.com/NordionInc.
(613) 592-3400 x. 2414
Cell: (613) 291-3689
SOURCE Nordion Inc.